Tacrolimus for the Treatment of Superficial Kaposiform Hemangioendothelioma and Tufted Angioma

Last updated: May 4, 2024
Sponsor: West China Hospital
Overall Status: Active - Recruiting

Phase

2

Condition

Hemangioma

Kaposi's Sarcoma

Skin Cancer

Treatment

Tacrolimus ointment

Clinical Study ID

NCT04056962
813
  • Ages < 18
  • All Genders

Study Summary

The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Children with superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA)

Exclusion

Exclusion Criteria:

  • Hypersensitivity to Tacrolimus Mucosal Kaposiform hemangioendothelioma (KHE) andtufted angioma (TA)

Study Design

Total Participants: 50
Treatment Group(s): 1
Primary Treatment: Tacrolimus ointment
Phase: 2
Study Start date:
September 01, 2019
Estimated Completion Date:
October 28, 2024

Study Description

Kaposiform hemangioendothelioma (KHE) and tufted angiomas (TA) are rare vascular tumors, which are apparent predominantly in infancy or early childhood. Currently, no standard treatment regimens exist for KHE/TA. The aim of this study was to evaluate the efficacy and safety of topical application of tacrolimus at different concentrations for superficial Kaposiform hemangioendothelioma (KHE) and tufted angioma (TA).

Connect with a study center

  • West China Hospital of Sichuan University

    Chengdu, Sichuan 610041
    China

    Active - Recruiting

+−

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.